Free tool · No account
Clinical trials for leukemia
Leukemia covers several very different diseases (AML, ALL, CLL, CML), each with its own trials. Naming the specific type, and any known genetic marker, makes the search far more useful.
1,386 recruiting trials. Showing a sample.
- recruitingNCT03911128
A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive system for stratification and treatment of ALL in ...
Listed by the study for Leukemia, Acute Lymphoblastic. Record updated 2026-08-13.
Sponsored by Mats HeymanFull details on ClinicalTrials.gov → - recruitingEARLY_Phase 1NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Listed by the study for Acute Lymphoblastic Leukemia, in Relapse. Record updated 2020-10-28.
Sponsored by Zhejiang UniversityFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT03938987
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).
Listed by the study for Precursor Cell Lymphoblastic Leukemia-Lymphoma. Record updated 2026-02-09.
Sponsored by University of AlbertaFull details on ClinicalTrials.gov → - recruitingNCT02677064
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. A...
Listed by the study for Acute Leukemia. Record updated 2026-07-24.
Sponsored by Memorial Sloan Kettering Cancer CenterFull details on ClinicalTrials.gov → - recruitingNCT06891144
Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy
This observational epidemiological study targets patients aged 60 and over with de novo or secondary acute myeloblastic leukemia suitable for intensive receive intensive induction therapy as defined by the group. The main aim of the study is to determine the epidemiological ch...
Listed by the study for AML, Adult. Record updated 2025-03-24.
Sponsored by French Innovative Leukemia OrganisationFull details on ClinicalTrials.gov → - recruitingNCT05283993
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and resp...
Listed by the study for Plasma Cell Leukemia. Record updated 2026-09-16.
Sponsored by Peking University First HospitalFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT03471260
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of ...
Listed by the study for Acute Myeloid Leukemia. Record updated 2026-09-14.
Sponsored by M.D. Anderson Cancer CenterFull details on ClinicalTrials.gov → - recruitingNANCT06529250
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
AML is highly heterogeneous in pathogenesis, and CEBPA double-mutated (CEBPAdm) AML is a common type of leukemia in China. Currently, no targeted therapies for CEBPAdm, and chemotherapy and transplantation are still the treatment options for CEBPA double-mutated AML. At presen...
Listed by the study for AML. Record updated 2026-08-10.
Sponsored by Institute of Hematology & Blood Diseases Hospital, ChinaFull details on ClinicalTrials.gov → - recruitingPhase 1NCT06037018
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell non-Hodgkin lymphoma and B-cell lymphocytic leukemia.
Listed by the study for Acute Lymphoblastic Leukaemia. Record updated 2025-09-22.
Sponsored by CytoCares IncFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06849713
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Listed by the study for Chronic Lymphocytic Leukemia. Record updated 2026-08-11.
Sponsored by Massachusetts General HospitalFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-10-12. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this leukemia trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.